GSK (GSK) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.34
- EPS estimate
- $1.28
- EPS surprise
- +4.81%
- Revenue surprise
- +1.12%
- Revenue
- $11.2B
- Revenue estimate
- $11.1B
- Reported
- Jul 28, 2026
GSK reported Q2 2026 results on July 28, 2026. Earnings per share were $1.34, ahead of the $1.28 estimate by 4.81%. Revenue was $11.2 billion, 1.12% above the $11.1 billion consensus. Compared with Q2 2025, EPS rose about 8% from $1.24 and revenue rose about 5.7% from $10.6 billion.
Annual EPS rose each year, from $3.39 in 2022 to $3.88 in 2023, $4.06 in 2024 and $4.60 in 2025. The first half of 2026 adds up to $2.60 per share, against $2.44 a year earlier. The fourth quarter has been the weakest of each year, at $0.58 to $0.74 per share, while the high in the table is Q3 2025 at $1.46. Quarterly revenue dropped from $12.2 billion in Q1 2022 to $8.3 billion in Q2 2022 and has ranged between $10.0 and $11.8 billion over the last six quarters. GSK beat the EPS estimate in all 20 quarters shown.
GSK reported its third quarter between October 27 and November 2 in each of the past five years. That points to late October or early November 2026 for the Q3 2026 report. It will show how results compare with Q3 2025's $1.46 per share.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 28, 2026 | $1.28 | $1.34 | +4.81% | $11.2B | SEC |
| Q1 2026 | Apr 29, 2026 | $1.15 | $1.26 | +8.75% | $10.3B | SEC |
| Q4 2025 | Feb 4, 2026 | $0.64 | $0.70 | +8.50% | $11.8B | SEC |
| Q3 2025 | Oct 29, 2025 | $1.26 | $1.46 | +15.87% | $11.3B | SEC |
| Q2 2025 | Jul 30, 2025 | $1.17 | $1.24 | +5.58% | $10.6B | SEC |
| Q1 2025 | Apr 30, 2025 | $1.04 | $1.20 | +14.83% | $10.0B | SEC |
| Q4 2024 | Feb 5, 2025 | $0.49 | $0.58 | +18.70% | $10.2B | SEC |
| Q3 2024 | Oct 30, 2024 | $1.15 | $1.29 | +12.25% | $10.4B | SEC |
| Q2 2024 | Jul 31, 2024 | $0.98 | $1.11 | +14.01% | $10.1B | SEC |
| Q1 2024 | May 1, 2024 | $0.92 | $1.08 | +16.85% | $9.2B | SEC |
| Q4 2023 | Jan 31, 2024 | $0.74 | $0.74 | +0.08% | $10.3B | SEC |
| Q3 2023 | Nov 1, 2023 | $1.11 | $1.22 | +9.72% | $9.9B | SEC |
| Q2 2023 | Jul 26, 2023 | $0.89 | $1.00 | +12.26% | $9.3B | SEC |
| Q1 2023 | Apr 26, 2023 | $0.83 | $0.92 | +11.44% | $8.7B | SEC |
| Q4 2022 | Feb 1, 2023 | $0.55 | $0.64 | +16.61% | $9.1B | SEC |
| Q3 2022 | Nov 2, 2022 | $0.90 | $1.08 | +19.64% | $9.0B | — |
| Q2 2022 | Jul 27, 2022 | $0.64 | $0.84 | +30.88% | $8.3B | — |
| Q1 2022 | Apr 27, 2022 | $0.79 | $0.83 | +4.98% | $12.2B | — |
| Q4 2021 | Feb 9, 2022 | $0.66 | $0.70 | +5.53% | $12.9B | — |
| Q3 2021 | Oct 27, 2021 | $0.79 | $1.01 | +28.03% | $12.4B | — |
Quarterly revenue
Frequently asked questions
When did GSK (GSK) last report earnings?
GSK last reported on Jul 28, 2026, covering fiscal Q2 2026.
Did GSK beat earnings estimates?
Yes. GSK reported EPS of $1.34 for Q2 2026 against a $1.28 estimate — a 4.81% beat.
How much revenue did GSK report last quarter?
GSK reported $11.2B in revenue for Q2 2026, against a consensus estimate of $11.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.